Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Core Viewpoint - Scilex Holding Company has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Quarterly Report for the quarter ended September 30, 2024, and continues to focus on non-opioid pain management products and potential joint ventures for treating neurodegenerative and cardiometabolic diseases [1]. Company Overview - Scilex Holding Company is based in Palo Alto, California, and specializes in acquiring, developing, and commercializing non-opioid pain management products for both acute and chronic pain [3][5]. - The company aims to address high unmet needs in the market with non-opioid therapies and is dedicated to improving patient outcomes [3]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved by the FDA for neuropathic pain relief associated with postherpetic neuralgia [3]. - ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [3]. - Gloperba, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [3]. Product Candidates - Scilex has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status from the FDA [4]. - SP-104, a low-dose naltrexone hydrochloride delayed-release capsule for fibromyalgia treatment [4]. Joint Venture - The company is in the process of forming a joint venture with IPMC Company, which aims to expand its focus to neurodegenerative and cardiometabolic diseases [1][8].